Nilotinib | List of Frontiers open access articles

Original Research

Published on 16 Nov 2023

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

in Hematology

Bingbing Wen
Yuming Zhang
Haiqing Lin
Jin Lou
Chuangqing Tu
Yirong Jiang
Xiaolian Liu
Yan Chen
Huiqing He
Zelin Liu

Frontiers in Medicine

doi 10.3389/fmed.2023.1267512

2,780 views

Case Report

Published on 10 Jul 2020

Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option

in Pharmacology of Anti-Cancer Drugs

Hyun Yang
Pil Soo Sung
Eun Sun Jung
Sungwoo Cho
Si Hyun Bae
Dong-Wook Kim

Frontiers in Oncology

doi 10.3389/fonc.2020.01160

4,850 views
6 citations

Original Research

Published on 03 Jul 2020

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

in Cardiovascular and Smooth Muscle Pharmacology

Hélène Haguet
Céline Bouvy
Anne-Sophie Delvigne
Elise Modaffari
Adeline Wannez
Pierre Sonveaux
Jean-Michel Dogné
Jonathan Douxfils

Frontiers in Pharmacology

doi 10.3389/fphar.2020.01007

8,988 views
31 citations

Original Research

Published on 01 Feb 2022

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

in Hematologic Malignancies

Anna Sicuranza
Ilaria Ferrigno
Elisabetta Abruzzese
Alessandra Iurlo
Sara Galimberti
Antonella Gozzini
Luigiana Luciano
Fabio Stagno
Antonella Russo Rossi
Nicola Sgherza

Frontiers in Oncology

doi 10.3389/fonc.2022.835563

4,174 views
16 citations

Systematic Review

Published on 29 Sep 2022

Nilotinib in Parkinson's disease: A systematic review and meta-analysis

in Parkinson’s Disease and Aging-related Movement Disorders

Xiaolu Xie
Ping Yuan
Liqiu Kou
Xiu Chen
Jun Li
Yaling Li

Frontiers in Aging Neuroscience

doi 10.3389/fnagi.2022.996217

8,322 views
17 citations

Original Research

Published on 20 Feb 2014

A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease

in Cellular Neurophysiology

Akie Tanabe
Yukio Yamamura
Jiro Kasahara
Ryoma Morigaki
Ryuji Kaji
Satoshi Goto

Frontiers in Cellular Neuroscience

doi 10.3389/fncel.2014.00050

10,284 views
51 citations

Methods

Published on 26 May 2021

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy

in Hematologic Malignancies

Lidia Borghi
Gianantonio Rosti
Alessandro Maggi
Massimo Breccia
Eros Di Bona
Alessandra Iurlo
Gaetano La Barba
Paolo Sportoletti
Francesco Albano
Sara Galimberti

Frontiers in Oncology

doi 10.3389/fonc.2021.638689

4,945 views
1 citation

Case Report

Published on 13 Sep 2022

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event

in Hematologic Malignancies

Raffaella Pasquale
Cristina Bucelli
Valentina Bellani
Manuela Zappa
Alessandra Iurlo
Daniele Cattaneo

Frontiers in Oncology

doi 10.3389/fonc.2022.1012268

3,306 views
5 citations

Review

Published on 08 Nov 2022

Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis

in Cardio-Oncology

Sicong Li
Jinshan He
Xinyi Zhang
Yuchun Cai
Jian Liu
Xiaoyan Nie
Luwen Shi

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2022.966182

12,201 views
27 citations

Original Research

Published on 07 Feb 2023

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

in Cardio-Oncology

Rafael Amorim Belo Nunes
Precil Diego Miranda de Menezes Neves
Leandro Menezes Alves da Costa
Philip Bachour
Marcelo José de Carvalho Cantarelli
Gustavo Bernardes de Figueiredo Oliveira
Álvaro Avezum Jr.

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2023.888366

6,868 views
4 citations

Original Research

Published on 07 Jan 2025

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa

in Drugs Outcomes Research and Policies

Rochelle Woudberg
Edina Sinanovic

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1511603

2,996 views
2 citations

Original Research

Published on 12 Jun 2018

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

in Atherosclerosis and Vascular Medicine

Marianne G. Pouwer
Elsbet J. Pieterman
Lars Verschuren
Martien P. M. Caspers
Cornelis Kluft
Ricardo A. Garcia
Jurjan Aman
J. Wouter Jukema
Hans M. G. Princen

Frontiers in Cardiovascular Medicine

doi 10.3389/fcvm.2018.00055

11,141 views
65 citations

PDF-read only

Review

Published on 26 Nov 2021

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review

Muhammad Darwin Prenggono
Alfi Yasmina
Misna Ariyah
Tenri Ashari Wanahari
Nuvita Hasrianti

Oncology Reviews

doi 10.4081/oncol.2021.547

Case Report

Published on 08 Jun 2022

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19

in Hematologic Malignancies

Chengxin Luan
Haixia Wang
Junjie Zhou
Xiaoyu Ma
Zhangbiao Long
Xin Cheng
Xiaowen Chen
Ruixiang Xia
Jian Ge

Frontiers in Oncology

doi 10.3389/fonc.2022.921587

2,951 views
2 citations

Original Research

Published on 18 Mar 2022

c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease

in Membrane Traffic and Organelle Dynamics

Tamara Marín
Andrés E. Dulcey
Fabián Campos
Catalina de la Fuente
Mariana Acuña
Juan Castro
Claudio Pinto
María José Yañez
Cristian Cortez
David W. McGrath

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2022.844297

8,728 views
18 citations

Original Research

Published on 05 Sep 2025

Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study

in Pharmacology of Anti-Cancer Drugs

Ying Liu
Taoyan Lin
Boxin Zhao
Yilei Li
Ping Zheng

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1676800

1,934 views

Articles

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China

Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option

The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)

Nilotinib in Parkinson's disease: A systematic review and meta-analysis

A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson’s disease

Perspectives and Emotional Experiences of Patients With Chronic Myeloid Leukemia During ENESTPath Clinical Trial and Treatment-Free Remission: Rationale and Protocol of the Italian Substudy

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event

Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: A systematic review, meta-analysis and integrative bioinformatics analysis

Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19

c-Abl Activation Linked to Autophagy-Lysosomal Dysfunction Contributes to Neurological Impairment in Niemann-Pick Type A Disease

Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study